Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1661-1680 of 1,738 trials

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Chronic Urticaria: Study of BLU-808

We are testing a new medication, BLU-808, for people with chronic inducible and spontaneous urticaria. The study aims to understand its safety and how well it may help reduce symptoms.

Chronic Urticaria3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

CEB-01 for Pediatric Abdominal Tumors

We are testing a new treatment for children with certain types of abdominal tumors to see if it is safe and effective alongside standard care. This study focuses on children from birth to under 18 years old.

Desmoplastic Small Round Cell TumorFibrolamellar Hepatocellular CarcinomaExtracranial Malignant Rhabdoid Tumor6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Psoriasis in Children: IDP-122 Lotion Study

We are testing a new lotion for children with moderate to severe plaque psoriasis to see how safe it is and how well it is absorbed into the body. This study will help us understand its effects on children's hormonal systems.

Plaque Psoriasis≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyNeurology

Clonidine for Preventing Agitation in Young Children After Anesthesia

We are studying whether clonidine can help reduce agitation and pain in children under one year after surgery. The trial also examines its safety and effects on nausea and opioid use.

Postoperative Agitation≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPediatrics

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesNeurology

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHepatologyNeurology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Ulcerative Colitis: Testing OD-07656

We are studying a new treatment called OD-07656 for people with moderately to severely active ulcerative colitis. The trial aims to evaluate its safety and effectiveness compared to another therapy.

Ulcerative ColitisEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine